Physician profile
David D Suh
NPI 1366436297
$11,185.76
in general payments reported to CMS, 2019-2025
48 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,854 · 2020: $1,847 · 2021: $1,996 · 2022: $1,589 · 2023: $1,278 · 2024: $1,326 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,899.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,576.28 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,272.85 | 2019-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $891.57 | 2019-2025 | Lifevest |
| Pfizer INC. | $841.74 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $808.66 | 2019-2025 | Jardiance |
| Amgen INC. | $795.49 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $583.25 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $581.33 | 2020-2025 | |
| Amarin Pharma, INC. | $571.30 | 2020-2022 | |
| Novo Nordisk INC | $449.89 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $313.08 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $235.37 | 2019-2025 | Camzyos |
| Boston Scientific Corporation | $210.14 | 2022-2024 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $204.32 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Covidien LP | $182.48 | 2019 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $151.94 | 2025 | Attruby |
| Lundbeck LLC | $143.26 | 2019-2020 | |
| Baxter Healthcare | $141.16 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Edwards Lifesciences Corporation | $120.78 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sanofi-Aventis U.S. LLC | $109.28 | 2019-2024 | |
| Abbott Laboratories | $108.77 | 2021-2025 | Mitraclip |
| Bayer Healthcare Pharmaceuticals INC. | $104.49 | 2021-2024 | |
| Alnylam Pharmaceuticals INC. | $103.25 | 2021-2025 | Amvuttra, Onpattro |
| Glaxosmithkline, LLC. | $97.61 | 2019-2023 | Trelegy Ellipta |
| Inspire Medical Systems, INC. | $96.12 | 2024-2025 | Inspire |
| Vital Connect, INC | $80.90 | 2024 | Vitalpatch Rtm |
| Regeneron Healthcare Solutions, INC. | $64.07 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $37.56 | 2023-2024 | Inpefa |
| Kestra Medical Technology Services, INC. | $34.59 | 2023 | Assure Wcd |
| Medicomp INC | $27.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $26.17 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $24.78 | 2024 | Arcalyst |
| Cvrx, INC. | $23.27 | 2023 | Barostim Neo System |
| Lilly USA, LLC | $23.14 | 2020 | |
| Idorsia Pharmaceuticals US INC | $20.05 | 2025 | Tryvio |
| Philips North America LLC | $19.03 | 2020 | |
| Cardiva Medical, INC. | $17.68 | 2022 | |
| Janssen Biotech, INC. | $16.69 | 2024 | Stelara |
| Cleerly, INC. | $15.55 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Irhythm Technologies, INC. | $15.08 | 2024 | Zio Xt Patch |
| Esperion Therapeutics, INC. | $14.46 | 2021 | |
| Gilead Sciences, INC. | $13.71 | 2019 | |
| Vivus LLC | $11.84 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $5.78 | 2025 | Rhythm Express |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Suh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.